|
- Insulin Human Regular: IV vs. Subcutaneous - Expert Guide
We’ll explore the key distinctions between intravenous (IV) and subcutaneous (sub-Q) injections of regular human insulin, clarifying when each method is appropriate and highlighting the crucial factors to consider for optimal blood sugar control
- Subcutaneous Insulin Versus Traditional Intravenous Insulin Infusion in . . .
Background: Intravenous (IV) insulin infusions are the current standard of care for treatment of diabetic ketoacidosis (DKA) Subcutaneous (SQ) insulin, however, may also be a safe and effective alternative
- The Right Route: The Site of Injection Matters
The IV route properties allow it to be the desirable route when treating hyperkalemia given the faster onset allowing for quicker movement of potassium intracellularly Subcutaneous dosing produces gentler effects on glucose or electrolytes IV insulin may be ideal for a patient on the threshold of DKA, but not yet ready for an insulin drip
- POTD: Insulin in the ER — Maimonides Emergency Medicine Residency
Subcutaneous is the only dosage route for long-acting insulin but rapid and short-acting insulin can be given subcutaneous or intravenous IV insulin should only be used when you are treating hyperkalemia, DKA or HHS Otherwise, you should give insulin subq
- Continuous Insulin Infusion: When, Where, and How? - PMC
IV insulin has a very short duration of action (minutes), and the onset of basal subcutaneous insulin is 1-2 hours Thus, IV insulin should be continued for 1-2 hours after the first administration of subcutaneous basal insulin
- IV Insulin for Hospitalized Patients
it is recommended that patients in the intensive care unit (ICU) receive intravenous (IV) insulin infusion when BG levels are >180 mg dL1,2 Treatment for hyperglycemia must be individualized to avoid overly intensive management
- Subcutaneous vs. IV insulin - Clinical Advisor
I have heard that we can give subcutaneous (SC) regular insulin every one to two hours instead of giving an IV infusion Is that true?—Dennis A Fito, MD, Oklahoma City
- ISMP Guidelines for Optimizing Safe Subcutaneous Insulin Use in Adults
Institutionally-developed protocols addressing the administration of subcutaneous insulin for patients who are receiving enteral or parenteral nutrition, transitioning from intravenous insulin, or designated to receive nothing by mouth (NPO) have been shown to decrease the incidence of hyperglycemia and hypoglycemia 23,35 One type of error seen
|
|
|